Elevated Tumor Lactate and Efflux in High-grade Prostate Cancer demonstrated by Hyperpolarized 13C Magnetic Resonance Spectroscopy of Prostate Tissue Slice Cultures
Authors:
- Renuka SriramRSRenuka Sriram
- Mark Van CriekingeMCMark Van Criekinge
- Justin DeLos SantosJSJustin DeLos Santos
- Fayyaz AhamedFAFayyaz Ahamed
- Hecong QinHQHecong Qin
- Rosalie NolleyRNRosalie Nolley
- Romelyn DeLos SantosRSRomelyn DeLos Santos
- Z. Laura TabatabaiZTZ. Laura Tabatabai
- Robert A. BokRBRobert A. Bok
- Kayvan R. KeshariKKKayvan R. Keshari
- Daniel B. VigneronDVDaniel B. Vigneron
- Donna M. PeehlDPDonna M. Peehl
Open Access
Abstract
Non-invasive assessment of the biological aggressiveness of prostate cancer (PCa) is needed for men with localized disease. Hyperpolarized (HP) 13C magnetic resonance (MR) spectroscopy is a powerful approach to image metabolism, specifically the conversion of HP [1-13C]pyruvate to [1-13C]lactate, catalyzed by lactate dehydrogenase (LDH). Significant increase in tumor lactate was measured in high-grade PCa relative to benign and low-grade cancer, suggesting that HP 13C MR could distinguish low-risk (Gleason score ≤3 + 4) from high-risk (Gleason score ≥4 + 3) PCa. To test this and the ability of HP 13C MR to detect these metabolic changes, we cultured prostate tissues in an MR-compatible bioreactor under continuous perfusion. 31P spectra demonstrated good viability and dynamic HP 13C-pyruvate MR demonstrated that high-grade PCa had significantly increased lactate efflux compared to low-grade PCa and benign prostate tissue. These metabolic differences are attributed to significantly increased LDHA expression and LDH activity, as well as significantly increased monocarboxylate transporter 4 (MCT4) expression in high- versus low- grade PCa. Moreover, lactate efflux, LDH activity, and MCT4 expression were not different between low-grade PCa and benign prostate tissues, indicating that these metabolic alterations are specific for high-grade disease. These distinctive metabolic alterations can be used to differentiate high-grade PCa from low-grade PCa and benign prostate tissues using clinically translatable HP [1-13C]pyruvate MR.Keywords
Funding Information
- National Institutes of Health (R01CA166655, P41EB013598, K99EB014328, P30CA008748)
- U.S. Department of War (W81XWH-10-1-0334, W81XWH-12-1-0328)
This publication has 65 references indexed in Scilit:
- Screening for Prostate Cancer: Early Detection or Overdetection?Annual Review of Medicine, 2012
- Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancerBMC Cancer, 2011
- Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environmentNMR in Biomedicine, 2011
- Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progressionBritish Journal of Cancer, 2010
- Time Trends and Local Variation in Primary Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2010
- Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerBritish Journal of Cancer, 2009
- Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of DiagnosisJNCI: Journal of the National Cancer Institute, 2009
- Evaluation of the ERETIC method as an improved quantitative reference for 1H HR‐MAS spectroscopy of prostate tissueMagnetic Resonance in Medicine, 2009
- Hyperpolarized 13C Lactate, Pyruvate, and Alanine: Noninvasive Biomarkers for Prostate Cancer Detection and GradingCancer Research, 2008
- Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissuesMagnetic Resonance in Medicine, 2008